INCY Incyte Pharma Earnings per share for the last twelve months

INCY (Incyte Corp) - company brandmark

Incyte Corporation is accelerating preclinical testing through the implementation of robotic laboratories. The EPS trend over the last 12 months visualizes this progress, with the metric currently standing at 1.87. The company relies on a strong scientific staff and high R&D investment, although geopolitical instability complicates the conduct of international research and the export of innovative therapies.

INCY (Incyte Corporation) Net earnings per share for the last 12 months history from 07/04/2022 to 11/15/2026

Incyte Pharma - analytical breakdowns and key metrics (INCY)

- current quotes and average value forecast:
Price Chart Incyte Pharma|INCY - Average Forecast Price
- market capitalization data:
Market Value Incyte|INCY - Business Value
- shareholders' equity book value data:
Book Value per Share Incyte|INCY - Company Net Assets|Market Value to Book Value Ratio incyte.com|INCY - Company Assets
- debt burden and liquidity indicators:
Debt to Equity Incyte Corporation|INCY - Long-Term Debt to Equity|Short-Term Debt to Equity Incyte Corp|INCY - Company Cumulative Debt|Debts to Book Capitalization Incyte Corp.|INCY - Long-Term Indebtedness|Company Current Liabilities Incyte|Quick Liquidity Indicator incyte.com
- net income and valuation multiples indicators:
INCY - Final Profit|Future Profit Incyte Corporation|INCY - Market Price to Net Income Ratio|Forward P/E Multiple Incyte Corp.|INCY - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Incyte Corporation|INCY - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Incyte|INCY - Earnings per share for the trailing year|Quarterly EPS earnings growth incyte.com|INCY - Earnings growth in current year|Net earnings per share growth forecast for next year Incyte Corporation
- revenue and sales details:
INCY - Company Annual Revenue|Company Future Sales Volume Incyte Pharma|INCY - Price to Sales|Forward P/S Multiple Incyte
Basic company analysis:incyte.com (INCY)
Mass-produced product of Incyte Corp.

The efficiency of implementing targeted oncology and hematology drugs within government procurement directly determines the ability of Incyte Corporation (INCY) to generate a sustainable cash flow. By analyzing the trailing 12-month EPS, an investor can see the actual return per share excluding the impact of share buybacks, which allows for the identification of true profitability trends and prevents overpaying for the asset.

Analysis of competing companies

HCM - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Nuvation Bio Inc|Day One (DAWN) - Earnings per share for the last twelve months|Earnings per share for the last 12 months MNPR|INBX (inhibrx.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months i-mabbiopharma.com (IMAB)|Earnings per share for the last twelve months Fennec (FENC)|HRTX - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Nuvectis NVCT|Coherus Biosciences - Earnings per share for the last twelve months|CRBP - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months cardiffoncology.com|BYSI: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BioAtla, Inc. BCAB|Net earnings per share for the last 12 months LIXT|Net earnings per one share for the last twelve months Citius Pharmaceuticals, Inc. CTXR|Net earnings per share for the last 12 months CLRB (Cellectar Biosciences)|BLRX (BioLineRx) - Earnings per share for the trailing year|Can-Fite BioPharma - Net earnings per share for the last 12 months|Earnings per share for the last four quarters APRE (Aprea)|Kazia Therapeutics Limited - Net earnings per share (EPS TTM)|Earnings per share for the trailing year SLXN (silexion.com)|NCNA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months chimerix.com (CMRX)|Earnings per share for the last twelve months Cyclacel|GTHX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) KRON|Net earnings per share (EPS TTM) Kintara Pharma (KTRA)|Earnings per share for the last twelve months Oncternal ONCT|PRTG (Portage Biotech) - Earnings per one share for the last 12 months